A5038717306- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Contact Dermatitis and Allergies
- Food Allergy and Anaphylaxis Research
- Asthma and respiratory diseases
- Bacillus and Francisella bacterial research
- Viral Infections and Immunology Research
- Acne and Rosacea Treatments and Effects
- Adrenal Hormones and Disorders
- Drug-Induced Adverse Reactions
- Poxvirus research and outbreaks
- Psoriasis: Treatment and Pathogenesis
- Skin Protection and Aging
- Intramuscular injections and effects
- Urticaria and Related Conditions
- Ocular Surface and Contact Lens
- melanin and skin pigmentation
University Medical Center Groningen
2019-2024
University of Groningen
2019-2024
Queen's University
2021
Bispebjerg Hospital
2021
University of Copenhagen
2021
Dialyse Centrum Groningen
2021
Hand eczema is a common inflammatory skin disorder. Health care providers need continuously updated information about the management of hand to ensure best treatment for their patients.To update European Society Contact Dermatitis guideline on diagnosis, prevention, and eczema.The Guideline Development Group (GDG) was established behalf ESCD. A call interest launched via ESCD website members' mailing list. Appraisal evidence therapeutic preventive interventions applied structured method...
Effective treatment options for patients with chronic hand eczema (CHE) are scarce. Dupilumab is licensed the of moderate-to-severe atopic dermatitis and has shown promising results in other studies.
Abstract Systemic treatment options for chronic hand eczema are limited. Dupilumab is used in atopic dermatitis (AD) but not licensed (isolated) eczema. In this observational prospective study we aimed to determine the response of dupilumab patients with AD. Adult and AD received s.c. at a 600 mg loading dose, followed by 300 every 2 weeks. Primary outcome was minimum improvement 75% on Hand Eczema Severity Index after 16 weeks (HECSI‐75). Secondary outcomes were severity, measured using...
Abstract Background The hands are a common predilection site of atopic dermatitis (AD). Dupilumab is licensed for the treatment AD but not chronic hand eczema (CHE), while CHE challenging to treat. Objectives To evaluate long‐term effect dupilumab on (HE) in patients with from BioDay Registry. Methods A prospective observational study adult HE, treated dupilumab. Patients HE severity at least moderate baseline were considered analysis. other concomitantly systemic immunosuppressive...
This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis a large prospective daily practice cohort. Data from Dutch BioDay Registry were used to assess developing disease, by performing univariate and multivariate logistic regression analyses. A total 469 included, which 152/469 (32.4%) developed disease. Multivariate analysis showed statistically significant association history any eye...
Data on chronic hand eczema and severity of in the general population is scarce. In this cross-sectional study, a questionnaire was sent to 135,950 Lifelines Cohort Study participants, order investigate prevalence Dutch population. total, 57,798 subjects were included. The lifetime 15.0% (95% confidence interval 14.7–15.3), 1-year 7.3% 7.1–7.6), self-reported physician-diagnosed 6.1% 5.9–6.3). 4.7% 4.5–4.9). majority (56.9%) with had almost clear at worst ever severe very 1.9% 1.8–2.1)....
Hand eczema is a common inflammatory skin condition of the hands whose pathogenesis largely unknown. More insight and knowledge disease on more fundamental level might lead to better understanding biological processes involved, which could provide possible new treatment strategies. We aimed profile transcriptome lesional palmar epidermal patients suffering from vesicular hand using RNA-sequencing. RNA-sequencing was performed identify differentially expressed genes in vs. non-lesional group...
Transcriptome analyses of vesicular hand eczema (VHE) indicated a large overlap with atopic dermatitis (AD). However, differentially expressed genes (DEGs) that differentiate VHE from AD are unknown.To identify distinctive transcriptional features in comparison to AD.We re-analysed RNA sequencing data 10 lesional palmar epidermal biopsies and performed DEG analyses. We adjusted the obtained results 57 whole skin upper extremities or trunk our criteria. Up- down-regulated DEGs both diseases,...
Vesicular hand eczema (VHE), a clinical subtype of (HE), showed limited responsiveness to alitretinoin, the only approved systemic treatment for severe chronic HE. This emphasizes need alternative approaches. Therefore, our study aimed identify drug repurposing opportunities VHE using transcriptomics and genomics data. We constructed gene network by combining 52 differentially expressed genes (DEGs) from with 3 quantitative trait locus (QTL) associated Through analysis, clustering,...
Alitretinoin is the only registered systemic treatment of severe chronic hand eczema (HE), but it most effective in hyperkeratotic HE.1 It has never been compared head-to-head studies to other immunomodulating drugs, for example, azathioprine, that can be used (off-label) HE. In one daily practice case series, patients showed moderate-to-good improvement their HE after with azathioprine.2 Based on this which patient was included, combined observations clinical practice, azathioprine could...
Eczema control is a new construct to be measured in atopic dermatitis (AD).Measuring patient-perceived eczema and treatment satisfaction AD patients, treated with dupilumab between 16 52 weeks.Cross-sectional questionnaire study. Patients from the Dutch BioDay registry completed Atopic Dermatitis Control Test (ADCT), Recap of (RECAP) Treatment Satisfaction Questionnaire for Medication, Version II (TSQM v. II), along other Patient Reported Outcome Measures (PROMs).104/157 patients responded...
Injected local anaesthetics have been reported to cause delayed-type reactions.1-3 A bullous type IV allergic reaction caused by lidocaine injected during a skin biopsy has once.4 51-year-old woman underwent trigger finger surgery in which 20 mg/mL with adrenaline 1:100 000 was subcutaneously as anaesthetic. Over the next 12 hours, she developed pruritic erythematous, vesicular and papular eruption on her right palm dorsum near fourth metacarpal bone. Approximately 24 hours later, vesicles...
This study identified risk factors for the development of dupilumab-associated ocular surface disease in patients with moderate-to-severe atopic dermatitis a large prospective daily practice cohort. Data from Dutch BioDay Registry were used to assess developing disease, by performing univariate and multivariate logistic regression analyses. A total 469 included, which 152/469 (32.4%) developed disease. Multivariate analysis showed statistically significant association history any eye...
<sec> <title>BACKGROUND</title> Dupilumab is the first antibody based treatment for atopic dermatitis (AD). It expected that many new options become available of diseases in near future. Despite high quality clinical trials, results are not always generalizable to daily practice. </sec> <title>OBJECTIVE</title> Registry collection real life data can add information gained trials. <title>METHODS</title> The BioDay prospectively collects regarding effectiveness and safety patients treated with...